Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.
Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.
Background: Achieving glycemic control without risking hypoglycemia imposes a major challenge
 in the management of toddlers and preschool children with Type 1 diabetes(T1D). Optimal
 insulin therapy for young children with T1D should provide effective glycemic control while
 minimizing the risk of hypoglycemia and hyperglycemia. Despite the advantages of the
 basal-bolus insulin regimens, hypoglycemia still presents a major barrier in achieving
 desirable glycemic control. Objectives: To compare the effectiveness of insulin degludec to
 insulin glargine and NPH in toddlers and preschool children with T1D in terms of glycosylated
 hemoglobin(HbA1C) and frequency of hypoglycemic episodes.
Inclusion Criteria:

 -  Toddlers and preschool children with T1D on insulin therapy

 Exclusion Criteria:

 -  patients with other medical conditions (i.e. celiac disease or autoimmune
 thyroiditis), patients with other types of diabetes mellitus (i.e. maturity onset
 diabetes of youth (MODY) and type 2 diabetes mellitus), patients with history of liver
 disease or any disorder likely to impair liver functions or elevated liver enzymes,
 renal impairment due to cause other than diabetes, hypertension, patients taking any
 vitamins or food supplements one month before study and participation in a previous
 investigational drug study within 3 months preceding screening.